Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PErsistence and safety of subcutaneous infliximab 1 year after switch from intravenous route in IBD patients in REMission.
Mathieu N, Hupé M, Heluwaert F, Rivière P, Hébuterne X, Chupin A, Abitbol V, Bouguen G, Vuitton L, Gornet JM, Montuclard C, Nancey S, Cadiot G, Wils P, Gilletta C, de Maissin A, Altwegg R, Chanteloup E, Plastaras L, Ah Soune P, Bourreille A, Stefanescu C, Seksik P, Simon M, Uzzan M, Andrau P, Rouillon C, Arondel Y, Buisson A, Peyrin-Biroulet L, Mboup B, Vicaut E, Laharie D. Mathieu N, et al. Among authors: buisson a. Clin Gastroenterol Hepatol. 2025 May 19:S1542-3565(25)00425-2. doi: 10.1016/j.cgh.2025.04.028. Online ahead of print. Clin Gastroenterol Hepatol. 2025. PMID: 40398832
Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures.
Fumery M, Pineton de Chambrun G, Stefanescu C, Buisson A, Bressenot A, Beaugerie L, Amiot A, Altwegg R, Savoye G, Abitbol V, Bouguen G, Simon M, Duffas JP, Hébuterne X, Nancey S, Roblin X, Leteurtre E, Bommelaer G, Lefevre JH, Brunetti F, Guillon F, Bouhnik Y, Peyrin-Biroulet L. Fumery M, et al. Among authors: buisson a. Clin Gastroenterol Hepatol. 2015 Oct;13(10):1770-5. doi: 10.1016/j.cgh.2015.04.185. Epub 2015 May 19. Clin Gastroenterol Hepatol. 2015. PMID: 26001338 Free article.
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Grimaud JC, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. Wils P, et al. Among authors: buisson a. Clin Gastroenterol Hepatol. 2016 Feb;14(2):242-50.e1-2. doi: 10.1016/j.cgh.2015.09.018. Epub 2015 Sep 30. Clin Gastroenterol Hepatol. 2016. PMID: 26432476 Free article.
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Bouhnik Y; Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group; Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif. Amiot A, et al. Among authors: buisson a. Clin Gastroenterol Hepatol. 2016 Nov;14(11):1593-1601.e2. doi: 10.1016/j.cgh.2016.02.016. Epub 2016 Feb 22. Clin Gastroenterol Hepatol. 2016. PMID: 26917043
320 results